SuccessTMS Brings Breakthrough Transcranial Magnetic Stimulation Treatment to West Palm Beach, Pledges to Treat One Million Patients in Honor of Founder's Sister

USA - English

• India - English

LAKE WORTH, Fla., Oct. 1, 2018 /PRNewswire-PRWeb/ -- Lake Worth, FL [October 1, 2018] – SuccessTMS, a provider offering compassionate care for Major Depressive Disorder (MDD), announced today its pledge to treat one million depression sufferers in honor of National Depression Awareness Month. Sparked by Founder Jonathan Michel's personal journey losing his sister, Alex, to suicide after her five-year battle with the disease, the facility's flagship location recently opened in Lake Worth to treat local residents. Michel and his leadership team have an aggressive expansion strategy and as they work toward their one million patient goal, plan to expand services throughout Florida and the rest of the country in the next three years.

"Depression robbed my sister of her hope for the future, and in her honor, I've made it my life's mission to restore hope in as many sufferers as possible," said Jonathan Michel, Founder, SuccessTMS. "NeuroStar Advanced Therapy TMS is proven, and it works. I've seen it give our patients their lives back and give them a true chance at remission from this horrible disease. In honor of Alex, I will work tirelessly to save as many lives as I can, National Depression Awareness Month is just the beginning."

In honor of National Depression Awareness Month, SuccessTMS will be providing a full treatment course, typically 36 therapy sessions, to a single patient, free of charge during the month of October. To be eligible, interested patients or their loved ones must simply submit their name, phone number and details of their personal depression journey to [email protected]. On October 31st, one patient entry will be randomly selected, contacted by the SuccessTMS team and then evaluated by a psychiatrist to ensure medical suitability before treatment begins.
SuccessTMS treats patients with NeuroStar® Advanced Therapy TMS, which uses magnetic pulses to awaken areas of the brain that are underactive in depression. With its advanced technology, NeuroStar Advanced Therapy offers doctors real-time feedback and delivers enhanced care with its precise and accurate targeting, providing reliable and consistent treatment. In an open-label clinical trial, 58% of patients significantly responded to treatment, and 37% achieved complete remission of their depression symptoms with NeuroStar Advanced Therapy TMS. Among people followed for 12 months after acute treatment, 68% retained their response and were considered in remission for the duration of a full year.

Since receiving FDA clearance in 2008 as a safe and effective treatment for adult patients with MDD, NeuroStar Advanced Therapy has become a game-changer in the treatment of depression and offers hope to the 5.5 million adults in the U.S. treated for depression who do not achieve remission with antidepressant medication. , , With widespread insurance coverage by most commercial and government health plans including Medicare and Tricare, the non-drug therapy is available by prescription and typically administered daily in a doctor's office for four to six weeks, with treatment sessions performed in under 19 minutes*. Unlike electroconvulsive therapy (ECT), NeuroStar Advanced Therapy is non-invasive, allows patients to resume daily activities immediately following treatment sessions. It is also free from systemic side effects often associated with antidepressant medications.

"It is a true privilege to work alongside passionate, dedicated colleagues at a practice with such a noble mission," said Dr. Lindsay Israel, Chief Medical Officer and Medical Director, SuccessTMS. "Jonathan knows firsthand the devastating and debilitating effects of depression, it is a disease that affects more than just the person diagnosed and truly touches entire families and communities. An empathetic approach to care, driven by proven treatment options like NeuroStar Advanced Therapy TMS, is the best way to ensure positive clinical outcomes and I'm excited to be offering that to depression sufferers and their families in our community."

SuccessTMS is located at 1926 10th Ave. N. Suite 410. The practice welcomes new patients and is open Monday – Friday from 9:00 a.m. – 5:00 p.m. To learn more, or to schedule an appointment visit successtms.com.

About SuccessTMS
SuccessTMS was created to help save the 1 million lives affected by depression, and in honor of Alex, a vibrant young woman who lost her personal battle with the disease. Transcranial magnetic stimulation (TMS) therapy is an alternative form of treatment for depression. SuccessTMS believes in providing a deeper and more compassionate level of care in order to maximize successful outcomes. Creating an experience that empathizes with the constant struggle of depression while focusing on positive attitudes and successful clinical outcomes, SuccessTMS strives to deliver the best medical care combined with an approach dedicated to making each patient feel welcomed, loved, and cared for.

About NeuroStar® Advanced Therapy
NeuroStar® Advanced Therapy is the established leader in transcranial magnetic stimulation (TMS), a non-invasive form of neuromodulation. NeuroStar Advanced Therapy is the #1 TMS choice of doctors, and is available in 49 states in the United States.

NeuroStar is widely reimbursed by most commercial and government health plans, including Medicare and Tricare. In addition, there are programs in place, such as NeuroStar Reimbursement Support, to help patients and providers obtain coverage and reimbursement for NeuroStar Advanced Therapy.

NeuroStar is indicated for the treatment of MDD in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode. In a NIMH-funded, independent, randomized controlled trial, patients treated with TMS using a clinical-trial version of the NeuroStar TMS System were four times more likely to achieve remission compared to patients receiving sham treatment (P = 0.0173; odds ratio = 4.05). The most common side effect is pain or discomfort at or near the treatment site, which usually resolves within one week. It is contraindicated in people with non-removable conductive metal in or near the head.

NeuroStar® is a registered trademark of Neuronetics, Inc. For more information and full safety and prescribing information, visit http://www.neurostar.com.

SOURCE SuccessTMS